Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sovleplenib in Warm Antibody Autoimmune Hemolytic Anemia
NCT05535933Phase 3Active, not recruiting
- Sponsor
- HUTCHMED
- Start
- Sep 2022
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sovleplenib in warm antibody autoimmune hemolytic anemia (WAIHA), sponsored by HUTCHMED. Started Sep 2022; status: active, not recruiting.
02
Drugs
sovleplenib
03
Conditions
warm antibody autoimmune hemolytic anemia (WAIHA)
Beyond the preview
Go deeper on NCT05535933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05535933.